Fresenius Kabi announced the availability of a single-needle venous access option for its Amicus extracorporeal photopheresis (ECP) system.
The company announced its availability at the 49th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT).
Fresenius Kabi first launched the Amicus Blue system with online ECP in Europe in 2019 with double-needle venous access only. The new update includes new software (v6.1) for the Amicus Separator and new software (v2.1) for the Phelix photoactivation device. It also features a new, single-use disposable kit configurable for single- or double-needle venous access. The system also enables clinicians to switch between single- and double-needle access at any time during a procedure.
“We are thrilled to enable the single-needle option for the Amicus Blue ECP system, which will allow physicians to treat patients with limited venous access,” said Christian Hauer, president of Fresenius Kabi MedTech. “This builds on our Amicus Blue vision to provide a versatile, multi-procedural instrument to support patients’ individual needs.”
Amicus ECP now has CE mark for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL). These skin manifestations of CTCL remain unresponsive to other forms of treatment.
Fresenius Kabi’s Amicus Separator also has European and U.S. approval for therapeutic plasma exchange, red blood cell exchange, mononuclear cell collection and platelet collection. The Amicus ECP System is not cleared for use in the U.S.
